Compare · RMD vs STVN
RMD vs STVN
Side-by-side comparison of ResMed Inc. (RMD) and Stevanato Group S.p.A. (STVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and STVN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 6.5x STVN ($5.26B).
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for STVN).
- RMD has more recent analyst coverage (25 ratings vs 24 for STVN).
- Company
- ResMed Inc.
- Stevanato Group S.p.A.
- Price
- -
- -
- Market cap
- $34.07B
- $5.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 24
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target
Latest STVN
- Deutsche Bank initiated coverage on Stevanato Group S.p.A.
- Officer Stocchi Mauro sold $293,454 worth of Ordinary Shares (13,649 units at $21.50), decreasing direct ownership by 3% to 400,000 units (SEC Form 4)
- UBS initiated coverage on Stevanato Group S.p.A.
- Stevanato Group to Participate in Two Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.
- Director Magistretti Elisabetta sold $41,084 worth of Ordinary Shares (2,045 units at $20.09), decreasing direct ownership by 41% to 2,930 units (SEC Form 4) to cover taxes
- Chief Financial Officer Dal Lago Marco sold $84,559 worth of Ordinary Shares (4,209 units at $20.09), decreasing direct ownership by 5% to 81,144 units (SEC Form 4) to cover withholding tax
- Director Santel Luciano sold $40,642 worth of Ordinary Shares (2,023 units at $20.09), decreasing direct ownership by 30% to 4,739 units (SEC Form 4) (withholding tax)
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.